[Therapeutic strategies of obstructive sleep apnea syndrome integrating combined treatments?].
Unité fonctionnelle: exploration et prise en charge des troubles du sommeil et de la vigilance, Hôtel-Dieu, Groupement hospitalier universitaire Ouest, Paris, France.
M-F
MF
Vecchierini
J-P
JP
Laaban
M
M
Desjobert
F
F
Gagnadoux
F
F
Chabolle
J-C
JC
Meurice
M
M
Sapène
P
P
Serrier
P
P
Lévy
D000428:Alcohol Drinking; D001569:Benzodiazepines / Q000009:adverse effects; D003131:Combined Modality Therapy; D045422:Continuous Positive Airway Pressure; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects; D008297:Male; D008691:Methadone / Q000009:adverse effects; D009294:Narcotics / Q000009:adverse effects; D009538:Nicotine / Q000009:adverse effects; D056888:Patient Positioning; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects; D010879:Piperazines / Q000009:adverse effects; D011187:Posture; D011687:Purines / Q000009:adverse effects; D019141:Respiratory System Agents / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D020181:Sleep Apnea, Obstructive / Q000503:physiopathology / Q000628:therapy*; D012893:Sleep Wake Disorders / Q000628:therapy; D013450:Sulfones / Q000009:adverse effects; D014665:Vasodilator Agents / Q000009:adverse effects; D015431:Weight Loss
D006993:Hypnotics and Sedatives; D009294:Narcotics; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D019141:Respiratory System Agents; D013450:Sulfones; D014665:Vasodilator Agents; D001569:Benzodiazepines; D009538:Nicotine; D000068677:Sildenafil Citrate; D008691:Methadone